SCHEMBL2028748

SCHEMBL2028748

O=S(=O)(Nc1cc(Cl)c(Sc2ccc3ccccc3c2)c(Cl)c1)c1ccc(Cl)nc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.49
ALDH1A1 P00352 3/20 0.47
GAA P10253 2/20 0.46
CCR2 P41597 1/20 0.43
PIK3CB P42338 1/20 0.43
LMNA P02545 3/20 0.42
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
ATM Q13315 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HPGD P15428 1/20 0.40
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.39
PKLR P30613 1/20 0.39
PGR P06401 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2037866 0.87 ALDH1A1 (0.46) PPARGALDH1A1GAACCR2LMNA
SCHEMBL2032678 0.83 SMN1; SMN2 (0.47) PPARGALDH1A1GAACCR2LMNA
SCHEMBL2034985 0.82 PPARG (0.56) PPARGALDH1A1GAACCR2PIK3CB
SCHEMBL2031882 0.78 PPARG (0.52) PPARGALDH1A1GAACCR2LMNA
SCHEMBL2031472 0.76 PPARG (0.59) PPARGLMNAMEN1KMT2AMAPT
SCHEMBL2036828 0.75 PPARG (0.45) PPARGALDH1A1GAACCR2LMNA
SCHEMBL2568163 0.73 GAA (0.64) ALDH1A1GAACCR2LMNAMAPK1
SCHEMBL2034935 0.72 PPARG (0.56) PPARGGAALMNA
SCHEMBL12585171 0.72 ALDH1A1 (0.46) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL2035210 0.70 ACLY (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968567-B2 Compounds for the modulation of PPARγ activity AMGEN INC. (US) 2011-06-28 US disclosed
US-7968567-B2 Compounds for the modulation of PPARγ activity AMGEN INC. (US) 2011-06-28 US disclosed
US-7968567-B2 Compounds for the modulation of PPARγ activity AMGEN INC. (US) 2011-06-28 US disclosed
US-20100113522-A1 COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY AMGEN INC. (US) 2010-05-06 US disclosed
US-20100113522-A1 COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY AMGEN INC. (US) 2010-05-06 US disclosed
US-20100113522-A1 COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY AMGEN INC. (US) 2010-05-06 US disclosed
US-7626033-B2 Compounds for the modulation of PPARγ activity AMGEN INC. (US) 2009-12-01 US disclosed
US-7626033-B2 Compounds for the modulation of PPARγ activity AMGEN INC. (US) 2009-12-01 US disclosed
US-20060264481-A1 Therapeutic modulation of PPARgamma activity AMGEN INC. (US) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264481-A1 Therapeutic modulation of PPARgamma activity PPARG, PPARA, PPARD PPARG 1/4885ALDH1A1 1672/4885GAA 1364/4885
US-20100113522-A1 COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY PPARG, PPARA, PPARD PPARG 1/4885ALDH1A1 1739/4885GAA 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.